Proactive Infliximab Optimization Using a Pharmacokinetic Dashboard Versus Standard of Care in Patients With Inflammatory Bowel Disease: The OPTIMIZE Trial

PHASE4Enrolling by invitationINTERVENTIONAL
Enrollment

124

Participants

Timeline

Start Date

November 1, 2021

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Crohn DiseaseUlcerative ColitisInflammatory Bowel Diseases
Interventions
DRUG

Infliximab

infliximab

Trial Locations (25)

10016

NYU Langone Health, New York

10029

Icahn School of Medicine at Mount Sinai, New York

10065

Weill Cornell Medical College, New York

19104

Children's Hospital of Philadelphia, Philadelphia

20500

Vanderbilt University Medical Center, Nashville

21201

University of Maryland Medical Center, Baltimore

28204

Atrium Health Center for Digestive Health, Charlotte

29425

Medical University of South Carolina, Charleston

33136

University of Miami, Miami

44195

Cleveland Clinic, Cleveland

53226

Medical College of Wisconsin, Milwaukee

55455

University of Minnesota, Minneapolis

60208

Northwestern University, Evanston

60637

University of Chicago Medicine, Chicago

61107

Rockford GI, Rockford

75390

University of Texas Southwestern Medical Center, Dallas

84132

University of Utah, Salt Lake City

06510

Yale University School of Medicine, New Haven

02115

Boston Children's Hospital, Boston

02215

Beth Israel Deaconess Medical Center, Boston

01805

Lahey Hospital and Medical Center, Burlington

03766

Dartmouth-Hitchcock Medical Center, Lebanon

02915

LifeSpan Brown University, Providence

Unknown

London Health Sciences Centre - Children's Hospital, London

McGill University Health Centre (MUHC) Montreal General Hospital, Montreal

All Listed Sponsors
collaborator

The Leona M. and Harry B. Helmsley Charitable Trust

OTHER

collaborator

Icahn School of Medicine at Mount Sinai

OTHER

lead

Beth Israel Deaconess Medical Center

OTHER